{"entity":{"id":"checkpoint-therapeutics","kind":"company","name":"Checkpoint Therapeutics","aka":["Checkpoint Therapeutics, Inc."],"tldr":"Checkpoint Therapeutics developed cosibelimab, an anti-PD-L1 antibody approved by the FDA in December 2024 for advanced cutaneous squamous cell carcinoma, and was acquired by Sun Pharma in 2025.","summary":"Checkpoint Therapeutics, a Massachusetts company founded within Fortress Biotech, developed cosibelimab (Unloxcyt), an anti-PD-L1 antibody with an intact Fc region designed to add antibody-dependent cell killing to checkpoint blockade. The FDA approved it in December 2024 for metastatic or locally advanced cutaneous squamous cell carcinoma not curable by surgery or radiation, after an earlier complete response letter over a manufacturing site. Sun Pharma agreed to acquire the company in 2025. Company facts are from the official website and FDA approval records.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.checkpointtherapeutics.com/"},{"label":"FDA: oncology and hematologic malignancies approval notifications","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"}],"tags":["fda-oce-applicant"],"related":[],"cancers":["cutaneous-scc"],"sections":["immunotherapy"],"technologies":[],"targets":[],"drugs":["cosibelimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Waltham, MA","country":"US","companyType":"biotech","website":"https://www.checkpointtherapeutics.com/","stage":"acquired","investors":[],"funding":[]},"route":"/companies/checkpoint-therapeutics/","neighbours":{"cancer":[{"id":"cutaneous-scc","kind":"cancer","name":"Cutaneous squamous cell carcinoma","route":"/cancers/cutaneous-scc/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"drug":[{"id":"cosibelimab","kind":"drug","name":"Cosibelimab","route":"/drugs/cosibelimab/"}],"trial":[{"id":"ck-301-101","kind":"trial","name":"CK-301-101","route":"/trials/ck-301-101/"},{"id":"nct04786964","kind":"trial","name":"Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC","route":"/trials/nct04786964/"}],"paper":[{"id":"paper-ck-301-101-jitc-2023","kind":"paper","name":"Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma","route":"/key-papers/paper-ck-301-101-jitc-2023/"}]}}